Genotype and smoking history affect risk of levodopa-induced dyskinesias in Parkinson's disease

Movement Disorders

Volumn 21, Issue 5, 2006, Pages 654-659

  Strong, Judith A ^a,b   Dalvi, Arif ^a,c   Revilla, Fredy J ^a   Sahay, Alok ^a   Samaha, Frederick J ^a   Welge, Jeffrey A ^a   Gong, Jianhua ^a,d   Gartner, Maureen ^a   Yue, Xia ^a   Yu, Lei ^a,e  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d AGRICULTURE AND AGRI FOOD CANADA   (Canada)

^e UNIVERSITY OF GUELPH   (Canada)

Author keywords

A118G; Dopamine D2 receptor; Dyskinesia; Levodopa; Mu opioid receptor; Smoking

Indexed keywords

CARBIDOPA PLUS LEVODOPA; DOPAMINE 2 RECEPTOR; LEVODOPA; MU OPIATE RECEPTOR;

ARTICLE; CONTROLLED STUDY; DINUCLEOTIDE REPEAT; DISEASE ASSOCIATION; DNA EXTRACTION; DRUG RESPONSE; DYSKINESIA; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PARKINSON DISEASE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUESTIONNAIRE; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; STUDENT T TEST; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; DYSKINESIA, DRUG-INDUCED; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE; POLYMORPHISM, GENETIC; RECEPTORS, DOPAMINE; RECEPTORS, OPIOID, MU; RISK; SMOKING;

EID: 33646945878     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.20785     Document Type: Article

References (32)

1. Katzenschlager R, Lees AJ. Treatment of Parkinson's disease: levodopa as the first choice. J Neurol 2002;249(Suppl 2):II19-II24.
2. Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001;16:448-458.
3. Gilgun-Sherki Y, Djaldetti R, Melamed E, Offen D. Polymorphism in candidate genes: implications for the risk and treatment of idiopathic Parkinson's disease. Pharmacogenomics J 2004,4:291-306.
4. Bezard E, Brotchie JM, Gross CE. Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Nat Rev Neurosci 2001;2:577-588.
5. Brotchie JM, Lee J, Venderova K. Levodopa-induced dyskinesia in Parkinson's disease. J Neural Transm 2005; 112:359-391.
6. Crossman AR. A hypothesis on the pathophysiological mechanisms that underlie levodopa- or dopamine agonist-induced dyskinesia in Parkinson's disease: implications for future strategies in treatment. Mov Disord 1990;5:100-108.
7. Jolkkonen J, Jenner P, Marsden CD. L-dopa reverses altered gene expression of substance P but not enkephalin in the caudateputamen of common marmosets treated with MPTP. Mol Brain Res 1995;32:297-307.
8. Henry B, Duty S, Fox SH, Crossman AR, Brotchie JM. Increased striatal pre-proenkephalin B expression is associated with dyskinesia in Parkinson's disease. Exp Neurol 2003;183:458-468.
9. Henry B, Brotchie JM. Potential of opioid antagonists in the treatment of levodopa-induced dysidnesias in Parkinson's disease. Drugs Aging 1996;9:149-158.
10. Henry B, Crossman AR, Brotchie JM. Effect of repeated L-dopa, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum. of the 6-hydroxydoparnine-lesioned rat. Exp Neurol 1999;155:204-220.
11. Piccini P, Weeks RA, Brooks DJ. Alterations in opioid receptor binding in Parkinson's disease patients with levodopa-induced dyskinesias. Ann Neurol 1997;42:720-726.
12. Bond C, LaForge KS, Tian M, et al. Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci USA 1998;95:9608-9613.
13. Oliveri RL, Annesi G, Zappia M, et al. Dopamine D2 receptor gene polymorphism and the risk of levodopa-induced dyskinesias in PD. Neurology 1999;53:1425-1430.
14. Hange XY, Grandy DK, Eubanks JH, Evans GA, Civelli O, Litt M. Detection and characterization of additional DNA polymorphisms in the dopamine D2 receptor gene. Genomics 1991;10:527-530.
15. Pritchard JK, Stephens M, Donnelly P. Inference of population structure using multilocus genotype data. Genetics 2000;155:945-959.
16. Comings DE. Why different rules are required for polygenic inheritance: lessons from studies of the DRD2 gene. Alcohol 1998; 16:61-70.
17. van den Bree MB, Owen MJ. The future of psychiatric genetics. Ann Med 2003;35:122-134.
18. Henry B, Fox SH, Crossman AR, Brotchie JM. Mu- and delta-opioid receptor antagonists reduce levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Exp Neurol 2001;171:139-146.
19. Chen L, Togasaki DM, Langston JW, Di Monte DA, Quik M. Enhanced striatal opioid receptor-mediated G-protein activation in L-dopa-treated dyskinetic monkeys. Neuroscience 2005;132:409-420.
20. Beyer A, Koch T, Schroder H, Schulz S, Hollt V. Effect of the A118G polymorphism on binding affinity, potency and agonist-mediated endocytosis, desensitization, and resensitization of the human mu-opioid receptor. J Neurochem 2004;89:553-560.
21. Allam MF, Campbell MJ, Hofman A, Del Castillo AS, Fernandez-Crehuet NR. Smoking and Parkinson's disease: systematic review of prospective studies. Mov Disord 2004;19:614-621.
22. Morens DM, Grandinetti A, Reed D, White LR, Ross GW. Cigarette smoking and protection from Parkinson's disease: false association or etiologic clue? Neurology 1995;45:1041-1051.
23. Lai BC, Marion SA, Teschke K, Tsui JK. Occupational and environmental risk factors for Parkinson's disease. Parkinsonism Relat Disord 2002;8:297-309.
24. Castagnoli K, Murugesan T. Tobacco leaf, smoke and smoking, MAO inhibitors, Parkinson's disease and neuroprotection; are there links? Neurotoxicology 2004;25:279-291.
25. Ives NJ, Stowe RL, Marro J, Counsell C, Macleod A, Clarke CE, Gray R, Wheatley K. Monoamine oxidase type B inhibitors in early Parkinson's disease: meta-analysis of 17 randomised trials involving 3525 patients. Br Med J 2004;329:593.
26. Alves G, Kurz M, Lie SA, Larsen JP. Cigarette smoking in Parkinson's disease: influence on disease progression. Mov Disord 2004;19:1087-1092.
27. Robinson TE, Berridge KC. Addiction. Annu Rev Psychol 2003; 54:25-53.
28. Batra V, Patkar AA, Berrettini WH, Weinstein SP, Leone FT. The genetic determinants of smoking. Chest 2003;123.1730-1739.
29. Millikan RC. Population stratification in epidemiologic studies of common genetic variants and cancer: quantification of bias. J Natl Cancer Inst 2001;93:156-158.
30. Khlat M, Cazes MH, Genin E, Guiguet M. Robustness of case-control studies of genetic factors to population stratification: magnitude of bias and type I error. Cancer Epidemiol Biomarkers Prev 2004;13:1660-1664.
31. Brevetti G, Oliva G, Silvestro A, Scopacasa F, Chiariello M. Prevalence, risk factors and cardiovascular comorbidity of symptomatic peripheral arterial disease in Italy. Atherosclerosis 2004; 175:131-138.
32. Substance Abuse and Mental Health Services Administration. Results from the 2003 national survey on drug use and health: national findings. Rockville, MD: Office of Applied Studies; 2004.